Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage

被引:1
作者
Xu, Yao [1 ]
Ye, Qing [2 ,4 ]
Shen, Wei [3 ,5 ]
机构
[1] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 4, Suzhou 215000, Jiangsu Provinc, Peoples R China
[2] Shanghai Jiao Tong Univ, Suzhou Kowloon Hosp, Dept Ophthalmol, Sch Med, Suzhou 215000, Jiangsu Provinc, Peoples R China
[3] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, Suzhou 215000, Jiangsu Provinc, Peoples R China
[4] 118 Wansheng St, Suzhou 215000, Jiangsu Provinc, Peoples R China
[5] 188 Shizi St, Suzhou 215000, Jiangsu Provinc, Peoples R China
关键词
conbercept; panretinal photocoagulation; high-risk proliferative diabetic retinopathy; vitreous hemorrhage; PARS-PLANA VITRECTOMY; VITREOMACULAR INTERFACE; MACULAR DEGENERATION; GROWTH-FACTOR; COMPLICATIONS; PREVALENCE; OUTCOMES; THERAPY;
D O I
10.18240/ijo.2024.06.11
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
AIM: To assess the clinical efficacy and safety of combining panretinal photocoagulation (PRP) with intravitreal conbercept (IVC) injections for patients with highrisk proliferative diabetic retinopathy (HR-PDR) complicated by mild or moderate vitreous hemorrhage (VH), with or without diabetic macular edema (DME). METHODS: Patients diagnosed with VH with/without DME secondary to HR-PDR and received PRP combined with IVC injections were recruited in this retrospective study. Upon establishing the patient's diagnosis, an initial IVC was performed, followed by prompt administration of PRP. In cases who significant bleeding persisted and impeded the laser operation, IVC was sustained before supplementing with PRP. Following the completion of PRP, patients were meticulously monitored for a minimum of six months. Laser therapy and IVC injections were judiciously adjusted based on fundus fluorescein angiography (FFA) results. Therapeutic effect and the incidence of adverse events were observed. RESULTS: Out of 42 patients (74 eyes), 29 were male and 13 were female, with a mean age of 59.17 +/- 12.74y (33-84y). The diabetic history was between 1wk and 26y, and the interval between the onset of visual symptoms and diagnosis of HR-PDR was 1wk-1y. The affected eye received 2.59 +/- 1.87 (1-10) IVC injections and underwent 5.5 +/- 1.02 (4-8) sessions of PRP. Of these, 68 eyes received PRP following 1 IVC injection, 5 eyes after 2 IVC injections, and 1 eye after 3 IVC injections. Complete absorption of VH was observed in all 74 eyes 5-50wk after initial treatment, with resolution of DME in 51 eyes 3-48wk after initial treatment. A newly developed epiretinal membrane was noted in one eye. Visual acuity significantly improved in 25 eyes. No complications such as glaucoma, retinal detachment, or endophthalmitis were reported. CONCLUSION: The study suggests that the combination of PRP with IVC injections is an effective and safe modality for treating diabetic VH in patients with HR-PDR.
引用
收藏
页码:1066 / 1072
页数:7
相关论文
共 50 条
[1]  
[Anonymous], 1981, OPHTHALMOLOGY, V88, P583
[2]   Complications of vitreoretinal surgery [J].
Belin, Peter J. ;
Parke, D. Wilkin, III .
CURRENT OPINION IN OPHTHALMOLOGY, 2020, 31 (03) :167-173
[3]   Early pars plana vitrectomy for proliferative diabetic retinopathy: update and review of current literature [J].
Berrocal, Maria H. ;
Acaba-Berrocal, Luis .
CURRENT OPINION IN OPHTHALMOLOGY, 2021, 32 (03) :203-208
[4]   Pars plana Vitrectomy [J].
Bopp, Silvia ;
Kellner, Ulrich .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2019, 236 (05) :705-722
[5]   Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study [J].
Chatziralli, Irini ;
Dimitriou, Eleni ;
Theodossiadis, George ;
Kazantzis, Dimitrios ;
Theodossiadis, Panagiotis .
ACTA DIABETOLOGICA, 2020, 57 (10) :1219-1225
[6]   Clinical efficacy and changes of serum VEGF-A, VEGF-B, and PLGF after conbercept treating neovascular age-related macular degeneration [J].
Chen, Xiao-Dong ;
Li, Chan ;
Ding, Guo-Long ;
Suo, Yan ;
Zhu, Yu-Sheng ;
Lu, Hui-Qin .
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2023, 16 (09) :1489-1495
[7]   Diabetic retinopathy [J].
Cheung, Ning ;
Mitchell, Paul ;
Wong, Tien Yin .
LANCET, 2010, 376 (9735) :124-136
[8]   Influence of the Vitreomacular Interface on Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials [J].
Cuilla, Thomas A. ;
Ying, Gui-shuang ;
Maguire, Maureen G. ;
Martin, Daniel F. ;
Jaffe, Glenn J. ;
Grunwald, Juan E. ;
Daniel, Ebenezer ;
Toth, Cynthia A. .
OPHTHALMOLOGY, 2015, 122 (06) :1203-1211
[9]   Prevalence and risk factors for diabetic retinopathy in the 40 to 80 year-old population in Yazd, Iran: The Yazd Eye Study [J].
Dehghan, Mohammad H. ;
Katibeh, Marzieh ;
Ahmadieh, Hamid ;
Nourinia, Ramin ;
Yaseri, Mehdi .
JOURNAL OF DIABETES, 2015, 7 (01) :139-141
[10]   Current knowledge on diabetic retinopathy from human donor tissues [J].
Eisma, Jessica H. ;
Dulle, Jennifer E. ;
Fort, Patrice E. .
WORLD JOURNAL OF DIABETES, 2015, 6 (02) :312-320